港股再鼎医药(09688)今日盘中大涨6%,引发市场关注。
公司宣布,其新药ZL-1310获得美国食品药品监督管理局(FDA)授予孤儿药资格认定。ZL-1310是一款用于治疗小细胞肺癌的高活力新型ADC药物,获此认定后将有望获得诸多优惠政策,包括申请费减免、研发税收抵免以及上市后一定期限的市场独占权。市场人士认为,孤儿药资格的获批将为公司该产品线带来较大利好,提升了ZL-1310药物未来的商业化前景,支撑了公司股价表现。
总的来说,再鼎医药利好消息传出后获得市场热捧,体现了投资者对公司创新药物管线以及未来发展前景的看好预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.